Welcome to our dedicated page for Aspira Women's Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspira Women's Health Inc. filings document the public-company record for a women's health diagnostics business focused on noninvasive gynecologic disease testing. Recent Form 8-K reports cover executive appointments, laboratory-services agreements, secured borrowing, equity-purchase arrangements, investor-presentation disclosures, and other material events involving the company's common stock and operating relationships.
Proxy materials describe board matters, executive compensation, equity awards, and shareholder voting items. Registration statements and related agreements disclose securities offerings, resale registration matters, common stock terms, filer status, and capital-structure effects. The filing record also includes a Form 12b-25 notice related to timing of the annual report and accounting completion for Aspira's Form 10-K.
Aspira Women's Health Inc. reported an insider equity award for one of its directors. On 12/02/2025, the reporting person received a stock option, described as a right to buy up to 314,811 shares of the company’s common stock at an exercise price of $0.35 per share. The option becomes exercisable on the same date, 12/02/2025, and is scheduled to expire on 12/02/2035.
Following this grant, the reporting person beneficially owns 314,811 derivative securities directly in the form of this stock option. The form is signed by /s/ John D. Fraser, indicating his role as the reporting person and confirming the director status in relation to Aspira Women's Health.
Aspira Women's Health Inc. director reports new stock option grant. A director of Aspira Women's Health Inc. received a stock option on 12/02/2025 covering 135,592 shares of common stock. The option has an exercise price of $0.35 per share, is listed as exercisable on 12/02/2025, and expires on 12/02/2035. After this transaction, the director beneficially owns 135,592 derivative securities, held directly.
Aspira Women's Health Inc. reported an insider equity award for director Winfred Parnell. On 12/02/2025, Parnell received a stock option to buy 185,178 shares of common stock at an exercise price of $0.35 per share. The option becomes exercisable on 12/02/2025 and expires on 12/02/2035. After this award, Parnell beneficially owned 185,178 derivative securities directly.
Aspira Women's Health Inc. director Jeffrey Cohen reported a new stock option grant. On 12/02/2025, he received an option to buy 213,518 shares of Aspira Women's Health common stock at an exercise price of $0.35 per share. The option is exercisable starting on the grant date and expires on 12/02/2035. After this grant, Cohen beneficially owns 213,518 derivative securities directly in the form of this stock option, giving him potential future ownership if he chooses to exercise.
Aspira Women's Health Inc. reported an insider equity award for a director. A Form 4 filing shows that on 12/02/2025 a director received a stock option (right to buy) covering 198,097 shares of Aspira Women's Health common stock at an exercise price of $0.35 per share. The option becomes exercisable on 12/02/2025 and expires on 12/02/2035. Following this grant, the director beneficially owns 198,097 derivative securities, held in direct ownership form.
Aspira Women’s Health Inc. reported Q3 2025 results. Revenue was $2,305,000, with gross profit of $1,383,000. Operating expenses were $2,962,000, leading to a loss from operations of $1,579,000. A non-cash loss from the change in fair value of warrant liabilities of $4,309,000 drove total other (expense) income, net to $(3,313,000), and the company recorded a net loss of $4,892,000 for the quarter.
For the nine months ended September 30, 2025, revenue was $6,988,000 and net loss was $9,411,000. Cash and cash equivalents were $3,809,000, working capital was $1,626,000, and long-term debt (DECD loan) was $1,100,000. Warrant liabilities increased to $5,280,000, largely tied to March 2025 warrants measured at fair value. Financing during 2025 included $3,484,000 in gross proceeds under the 2024 at-the-market program and $2,949,000 in gross proceeds from a September 2025 private placement.
The company disclosed substantial doubt about its ability to continue as a going concern within one year. Its common stock was delisted from Nasdaq in April 2025 and began trading on the OTC QX Best Market on October 14, 2025.
Aspira Women’s Health Inc. filed a Form 8-K announcing it issued a press release reporting financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.
The filing lists the company’s common stock trading on the OTC QX Market under the symbol AWHL.
Aspira Women’s Health Inc. filed an amended Form 8-K to correct the form of its Amended and Restated Series A Common Stock Warrant. The company stated that the version previously included with its September 25, 2025 disclosure inadvertently listed an incorrect termination date. The corrected warrant form is filed as Exhibit 4.1 and incorporated by reference.
The amendment is reported under Item 1.01 (Entry into a Material Definitive Agreement), with Item 3.02 (Unregistered Sales of Equity Securities) incorporating Item 1.01 by reference. The earliest event date is September 19, 2025.
Aspira Women’s Health filed Amendment No. 1 to a Form S-1 to register the resale of up to 29,226,527 shares of common stock by selling stockholders. The registered shares comprise: 5,915,850 issued on conversion of senior secured convertible notes, 11,848,177 issuable upon exercise of Amended and Restated March 2025 Warrants, 6,550,000 issued under the September 2025 Purchase Agreement, and 4,912,500 issuable upon exercise of September 2025 Warrants.
The company is not selling any securities in this prospectus and will not receive proceeds from stockholder resales. If the Amended and Restated March 2025 Warrants or September 2025 Warrants are exercised for cash, Aspira estimates it would receive $7,831,237. Sales may occur from time to time using methods described under “Plan of Distribution.” Aspira’s common stock trades on the OTCQB as AWHL; the closing price was $0.52 on September 29, 2025. Shares outstanding were 42,655,918 as of September 29, 2025.